Study Goal: This study looks at whether adding levocarnitine, a drug that provides extra carnitine (a nutrient made by the body), to standard chemotherapy can protect the liver in patients with certain types of blood cancer, like leukemia and lymphoma. Standard chemotherapy for these cancers includes a medicine called asparaginase, which can sometimes harm the liver, especially in young people aged 15 to 39.

Who Can Join? You can join if you are between 15 and 39 years old, newly diagnosed with the specified types of cancer, and meet certain health conditions. You cannot join if you have Down syndrome, certain liver diseases, or are pregnant or breastfeeding.

• Study Duration: Participation will last through the induction phase of chemotherapy.
• Visits Required: You may need to visit for routine check-ups and possibly blood tests.
• Risks and Benefits: The study aims to see if levocarnitine can reduce liver damage risks. As with any study, there might be unknown risks.

Study Design: Participants will be randomly placed into different groups to receive either standard chemotherapy alone or with added levocarnitine. Some participants may receive levocarnitine if liver issues develop during the study.